ViewRay (VRAYQ) Stock Price
ViewRay Price
Revenue has compounded at 49.3% per year over the past 10 years to 102.21 M USD. ViewRay's net margin stands at -105.0%, down from -94.4% several years earlier.
ViewRay stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of ViewRay over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ViewRay stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ViewRay's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | ViewRay Price |
|---|---|
| 8/28/2026 | 0.00 USD |
| 8/27/2026 | 0.00 USD |
| 8/26/2026 | 0.00 USD |
| 8/25/2026 | 0.00 USD |
| 8/24/2026 | 0.00 USD |
| 8/21/2026 | 0.00 USD |
| 8/20/2026 | 0.00 USD |
| 8/19/2026 | 0.00 USD |
| 8/18/2026 | 0.00 USD |
| 8/17/2026 | 0.00 USD |
| 8/14/2026 | 0.00 USD |
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
ViewRay Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
ViewRay Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 3.00 | 6.00 | 10.00 | 22.00 | 34.00 | 80.00 | 87.00 | 57.00 | 70.00 | 102.00 | – | – | 121.00 | 306.00 |
| – | 200.00 | 100.00 | 66.67 | 120.00 | 54.55 | 135.29 | 8.75 | -34.48 | 22.81 | 45.71 | – | – | – | 152.89 |
| -100.00 | -166.67 | -33.33 | -40.00 | -13.64 | 17.65 | 7.50 | -5.75 | -7.02 | 14.29 | 9.80 | – | – | 9.80 | 9.80 |
| -1.00 | -5.00 | -2.00 | -4.00 | -3.00 | 6.00 | 6.00 | -5.00 | -4.00 | 10.00 | 10.00 | 10.00 | 10.00 | 11.86 | 30.00 |
| -19.00 | -27.00 | -31.00 | -41.00 | -44.00 | -48.00 | -75.00 | -120.00 | -105.00 | -105.00 | -103.00 | -100.00 | -86.00 | -118.00 | -297.00 |
| -1,900.00 | -900.00 | -516.67 | -410.00 | -200.00 | -141.18 | -93.75 | -137.93 | -184.21 | -150.00 | -100.98 | – | – | -97.52 | -97.06 |
| -19.00 | -27.00 | -33.00 | -44.00 | -50.00 | -72.00 | -76.00 | -120.00 | -107.00 | -110.00 | -107.00 | – | – | -53.00 | -11.00 |
| – | 42.11 | 22.22 | 33.33 | 13.64 | 44.00 | 5.56 | 57.89 | -10.83 | 2.80 | -2.73 | – | – | – | -79.25 |
| 181.36 | 4.15 | 38.10 | 38.20 | 43.50 | 58.76 | 95.82 | 114.59 | 148.53 | 171.22 | 181.36 | 181.36 | 181.36 | 181.36 | 181.36 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales ViewRay generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ViewRay retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ViewRay's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares ViewRay has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ViewRay's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
ViewRay stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
ViewRay Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
ViewRay business model & stock analysis
ViewRay SWOT Analysis
Strengths
ViewRay Inc is a pioneering company in the field of image-guided radiation therapy, which allows for precise and targeted cancer treatments.
The company's flagship product, the MRIdian system, offers real-time MRI imaging during radiation therapy, providing physicians with detailed visual information for accurate treatment delivery.
ViewRay Inc has established a strong intellectual property portfolio, ensuring competitive advantage and legal protection for their innovative technology.
Weaknesses
As a relatively young company, ViewRay Inc may face challenges in market penetration and brand recognition compared to more established competitors.
The high cost of the MRIdian system may limit its adoption, especially in regions with budget constraints or insufficient insurance coverage.
ViewRay Inc's technology heavily relies on MRI, which may pose limitations in terms of availability and compatibility with existing radiation therapy centers.
Opportunities
The global demand for advanced cancer treatment options is increasing, providing opportunities for ViewRay Inc to expand its market share and revenue.
Continuous technological advancements and improvements in MRI technology can enhance the capabilities and competitiveness of ViewRay Inc's products.
Strategic partnerships with hospitals, research institutions, and healthcare providers can accelerate market penetration and facilitate product development.
Threats
The medical device industry is highly regulated, and changes in regulations or compliance requirements may impact ViewRay Inc's operations and market access.
Intense competition from well-established players in the radiation therapy market poses a threat to ViewRay Inc's market presence and growth potential.
Economic downturns, healthcare budget constraints, or changes in reimbursement policies can affect the adoption and affordability of ViewRay Inc's technology.
ViewRay Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
ViewRay Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
ViewRay historical P/E ratio, EBIT multiple, and P/S ratio
ViewRay annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
ViewRay shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
ViewRay stock splits
ViewRay Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/10/2023 | Maintained | Equal Weight | 51 | |
| 5/10/2023 | Downgrade | BuyNeutral | – | |
| 4/23/2023 | Maintained | Overweight | 50 | |
| 4/16/2023 | Downgrade | BuyHold | 56 | |
| 4/13/2023 | Downgrade | BuyHold | 56 | |
| 4/13/2023 | Downgrade | OutperformPerform | 62 | |
| 4/13/2023 | Maintained | Equal Weight | 51 | |
| 4/13/2023 | Downgrade | BuyNeutral | 52 | |
| 11/17/2022 | Maintained | Equal Weight | 51 | |
| 11/1/2022 | Maintained | Overweight | 50 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
ViewRay Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/8/2024 | -0.14USD | - | 21.42 MUSD | - | 2024 Q1 |
| 2/26/2024 | -0.13USD | - | 26.03 MUSD | - | 2023 Q4 |
EESG©
Eulerpool ESG Scorecard© for the ViewRay stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
ViewRay shareholder structure
| % | Name |
|---|---|
4.93485% | |
0.42989% | |
0.00545% | |
0.00534% | |
0.00002% | |
0.00000% |
ViewRay Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
22.60% | SEC ↗ | |
22.60% | SEC ↗ | |
22.40% | SEC ↗ | |
15.70% | SEC ↗ | |
12.90% | SEC ↗ | |
10.20% | SEC ↗ | |
10.20% | SEC ↗ | |
10.20% | SEC ↗ | |
8.78% | SEC ↗ | |
8.78% | SEC ↗ |
ViewRay Executives and Management Board
9 members · avg. age 53 · 33 % women
Mr. Paul Ziegler (51)
President, Chief Executive Officer
1.68 M USD
Management
Dr. James Dempsey (52)
Chief Scientific Officer · since 2004
Ms. Cassie Mahar (37)
Interim Chief Financial Officer
Mr. Adam Podbelski (44)
Senior Vice President- Commercial Operations
Board of Directors
Mr. Daniel Moore (62)
Independent Chairman of the Board
Mr. Brian Roberts (52)
Independent Director
Dr. Caley Castelein (52)
Independent Director
Ms. B. Kristine Johnson (71)
Independent Director
Ms. Karen Prange (58)
Independent Director
Frequently asked questions about ViewRay
ViewRay Inc is a medical technology company specializing in advanced radiation therapy solutions. Their business model revolves around developing and manufacturing MRIdian, a revolutionary MRI-guided radiotherapy system. By seamlessly integrating high-quality magnetic resonance imaging with precise radiation delivery, ViewRay aims to improve cancer treatment outcomes. This innovative technology allows real-time visualization of tumors and surrounding healthy tissues, enabling physicians to optimize treatment plans. ViewRay Inc focuses on providing cutting-edge solutions for the cancer care industry, ultimately aiming to enhance patient care and revolutionize the way radiation therapy is administered.
ViewRay Inc is primarily active in the healthcare industry.
The main competitors of ViewRay Inc in the market include Varian Medical Systems, Elekta AB, Accuray Incorporated, and Siemens Healthineers.
ViewRay Inc is a leading medical technology company focused on designing, manufacturing, and selling innovative radiation therapy systems. Founded in 2004, ViewRay has emerged as a pioneer in the field of MRI-guided radiation therapy, revolutionizing cancer treatment and improving patient outcomes. The company's flagship product, the MRIdian® system, integrates MRI technology with radiation therapy to provide real-time imaging and accurate target localization during treatment. ViewRay's cutting-edge solutions have garnered recognition worldwide and have been adopted by renowned cancer centers. With a strong commitment to innovation and patient care, ViewRay Inc continues to shape the future of radiation therapy.
ViewRay Inc has achieved several significant milestones throughout its history. Notably, the company received FDA clearance for its MRIdian Linac system, a state-of-the-art cancer treatment technology that combines MRI imaging with radiation therapy. This groundbreaking technology allows for real-time visualization of tumors during treatment, enabling precise and accurate delivery of radiation to targeted areas. The company has also successfully expanded its global presence, with installations of the MRIdian system in various prestigious cancer centers worldwide. Furthermore, ViewRay Inc has continually demonstrated its commitment to innovation and research, driving advancements in the field of radiation therapy for improved patient outcomes.
ViewRay Inc is primarily present in the United States.
ViewRay Inc represents values of innovation, precision, and patient-centricity. With a corporate philosophy focused on improving cancer treatment, ViewRay Inc develops advanced radiation therapy technology called MRIdian. Using real-time MRI guidance, this cutting-edge system enables physicians to deliver precise, personalized radiation therapy for cancer patients. Through continuous innovation and a commitment to improve the standard of care, ViewRay Inc aims to empower healthcare providers in their mission to effectively treat cancer. By integrating advanced imaging and treatment capabilities, the company strives to enhance patient outcomes and quality of life.
14 analysts currently rate the ViewRay stock: 8 recommend buying, 6 holding and 0 selling.
Converted at the current exchange rate, the ViewRay share trades at 0.00 EUR (0.00 USD).
The ViewRay share (VRAYQ) is listed on 3 stock exchanges, including: NASDAQ (VRAY), Frankfurt (6L9.F), München (6L9.MU).
ViewRay Inc. is an emerging American company that develops and sells innovative products and solutions in the field of medical technology. Their main business is the manufacturing and marketing of advanced radiation therapy systems that enable doctors to treat cancer patients with higher precision and efficacy. ViewRay Inc.'s business model includes the development and marketing of MRIdian®, a unique radiation therapy system based on magnetic resonance imaging (MRI). MRIdian® allows doctors to precisely control and monitor the radiation dose, ensuring precise and gentle treatment. This system is an ideal solution for patients with cancer in sensitive areas such as the brain, breast, or prostate. Another important aspect of ViewRay Inc.'s business model is conducting clinical studies to demonstrate the efficacy and safety of MRIdian® and other products in the pipeline. These studies are crucial for obtaining regulatory approval and market access. ViewRay Inc. is also engaged in research and development to create new technologies and products that allow doctors to more effectively combat cancer. For example, they are integrating artificial intelligence (AI) into MRIdian® systems to improve cancer diagnosis and treatment precision and speed. In addition to selling radiation therapy systems, ViewRay Inc. provides comprehensive service and support to ensure that the systems are always in optimal condition and patients are well cared for. They offer training for doctors and technical personnel to ensure they have the necessary knowledge and skills to safely and effectively use the MRIdian® system. ViewRay Inc. has also established partnerships and collaborations with other companies and organizations worldwide to expand its reach and offerings. For instance, they have a partnership with Elekta, a leading provider of medical imaging systems, to distribute their technology in Europe and Asia. In summary, ViewRay Inc. is an innovative company focused on developing and marketing high-quality radiation therapy systems to provide precise, gentle, and effective treatment for cancer patients. They are also actively involved in research and development to create new technologies and products for more effective cancer treatment. With a comprehensive range of service and support, as well as partnerships and collaborations, ViewRay Inc. is well positioned to continue growing and make a significant contribution to cancer fighting.
The revenue cannot currently be calculated for ViewRay.
The profit cannot currently be calculated for ViewRay.
The P/E ratio cannot be calculated for ViewRay at the moment.
The P/S cannot be calculated for ViewRay currently.
The Eulerpool Quality Score for ViewRay is 4/10.
The ISIN of ViewRay is US92672L1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ViewRay is A2AE2S. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ViewRay is VRAYQ. The ticker symbol is used to trade ViewRay shares on the stock exchange.
ViewRay paid dividends every year for the past 0 years.
ViewRay is assigned to the 'Health' sector.
The dividends of ViewRay are distributed in USD.
ViewRay stock
ViewRay Peer Group
ViewRay Ticker
ViewRay FIGI
All fundamentals and in-depth analysis of ViewRay
Our stock analysis for ViewRay stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ViewRay. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.